Skip to main content

Advertisement

SpringerLink
Log in

Endocan as a predictor of increased cardiovascular risk during the menopausal transition period

  • Gynecologic Endocrinology and Reproductive Medicine
  • Published:
Archives of Gynecology and Obstetrics Aims and scope Submit manuscript

Abstract

Purpose

Our aim was to investigate the serum endocan levels and carotid artery intima-media thickness (CIMT) measurements of pre- and postmenopausal patients to clarify the relationship between the menopausal transition and endothelial injury.

Methods

This cross-sectional study was conducted on women who were premenopausal and postmenopausal between January 2019 and June 2019. The patients were divided into two groups according to premenopausal (n = 32) and postmenopausal (n = 32) status. Serum endocan levels were assessed by enzyme-linked immunosorbent assay (ELISA). CIMT ultrasonographic measurements were determined. Hormonal and biochemical parameters were measured. The validated Menopause Rating Scale (MRS) questionnaire was used on all women.

Results

Serum endocan levels were significantly higher in the postmenopausal group than in the premenopausal group (222.90 ± 121.00 ng/L and 146.62 ± 41.88 ng/L, p = 0.033, respectively). The mean CIMT was significantly higher in the postmenopausal group than in the premenopausal cohort (0.70 ± 0.14 mm and 0.58 ± 0.11 mm, p < 0.001, respectively). A positive correlation was found between body mass index (BMI), systolic blood pressure (SBP), abdominal circumference (AC), and CIMT and postmenopausal serum endocan levels. Serum endocan levels with a cutoff point of 141.14 ng/L identified women with significant CIMT levels with sensitivity of 73.8% and specificity of 77.3%. A positive correlation was found between CIMT and endocan and total MRS scores.

Conclusion

Serum endocan levels were associated with CIMT during the menopausal transition period. Increased circulating endocan levels can be a predictor of cardiovascular risk in pre- and postmenopausal women.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Lloyd-Jones D, Adams RJ, Brown TM et al (2010) Heart disease and stroke statistics-2010 update: a report from the American Heart Association. Circulation 121:e46–e215

    PubMed  Google Scholar 

  2. Sowers M, Zheng H, Tomey K et al (2007) Changes in body composition in women over six years at midlife: ovarian and chronological aging. J Clin Endocrinol Metab 92:895–901

    Article  CAS  Google Scholar 

  3. Matthews KA, Meilahn E, Kuller LH et al (1989) Menopause and risk factors for coronary heart disease. N Engl J Med 321:641–646

    Article  CAS  Google Scholar 

  4. Sarrazin S, Adam E, Lyon M et al (2006) Endocan or endothelial cell specific molecule-1 (ESM-1): a potential novel endothelial cell marker and a new target for cancer therapy. Biochim Biophys Acta 1765:25–37

    CAS  PubMed  Google Scholar 

  5. Kali A, Shetty KS (2014) Endocan: a novel circulating proteoglycan. Indian J Pharmacol 46:579–583

    Article  CAS  Google Scholar 

  6. KoseM ES, Akpinar TS et al (2015) Serum endocan level and the severity of coronary artery disease: a pilot study. Angiology 66:727–731

    Article  Google Scholar 

  7. Qiu CR, Fu Q, Sui J et al (2017) Serum endothelial cell-specific molecule (endocan) levels in patients with acute myocardial infarction and its clinical significance. Angiology 68:354–359

    Article  CAS  Google Scholar 

  8. Xiong C, Zhao ZW, Chen ZY et al (2015) Elevated human endothelial cell specific molecule-1 level and its association with coronary artery disease in patients with hypertension. J Investig Med 63:867–870

    Article  CAS  Google Scholar 

  9. Stéphane S, Claude-Alain M, Dominique D, Philippe L, Maryse D (2010) Endocan as a biomarker of endothelial dysfunction in cancer. Diab Vasc Dis Res 02:47–52. https://doi.org/10.4172/1948-5956.1000022

    Article  CAS  Google Scholar 

  10. Lee W, Ku S-K, Kim S-W, Bae J-S (2014) Endocan elicits severe vascular inflammatory responses in vitro and in vivo. J Cell Physiol 229:620–630. https://doi.org/10.1002/jcp.24485

    Article  CAS  PubMed  Google Scholar 

  11. Altintas N, Mutlu LC, Akkoyun DC et al (2016) Effect of CPAP on new endothelial dysfunction marker, endocan in people with obstructive sleep apnea. Angiology 67:364–374

    Article  CAS  Google Scholar 

  12. Kanbay A, Ceylan E, İnönü Köseoğlu H et al (2016) Endocan: A novel predictor of endothelial dysfunction in obstructive sleep apnea syndrome. Clin Respir J 1:1–7

    Google Scholar 

  13. Coban A, Nehir S, Demirci H et al (2008) The impact on menopausal symptoms of marital adjustment and attitude toward menopausal of married women in the climacteric period. Fırat Univ Med J Health Sci 22:343–349

    Google Scholar 

  14. Besir FH, Yazgan S, Celbek G, Aydın M et al (2012) Normal values corralates of carotid intima-media thickness and affecting parameters in healthy adults. Anadolu Kardiyol Derg 12:427–433

    PubMed  Google Scholar 

  15. Harlow SD, Gass M, Hall JE et al (2012) Executive summary of the Stages of Reproductive Aging Workshop þ10: addressing the unfinished agenda of staging reproductive aging. J Clin Endocrinol Metab 97:1159–1168

    Article  CAS  Google Scholar 

  16. Muka T, Oliver-Williams C, Kunutsor S et al (2016) Association of age at onset of menopause and time since onset of menopause with cardiovascular outcomes, intermediate vascular traits, and all cause mortality: a systematic review and meta-analysis. JAMA Cardiol 1:767

    Article  Google Scholar 

  17. Balta S, Mikhailidis DP, Demirkol S et al (2015) Endocan: a novel inflammatory indicator in cardiovascular disease? Atherosclerosis 243:339–343

    Article  CAS  Google Scholar 

  18. Pfetsch V, Sanin V, Jaensch A et al (2017) Increased plasma concentrations of soluble ST2 independently predict mortality but not cardiovascular events in stable coronary heart disease patients: 13-year follow-up of the KAROLA study. Cardiovasc Drugs Ther 31:167–177

    Article  Google Scholar 

  19. Turk-Adawi K, Sarrafzadegan N, Fadhil I et al (2017) Cardiovascular disease in the Eastern Mediterranean region: epidemiology and risk factor burden. Nat Rev Cardiol 15:106–119

    Article  Google Scholar 

  20. Béchard D, Scherpereel A, Hammad H et al (2001) Human endothelial-cell specific molecule-1 binds directly to the integrin CD11a/CD18 (LFA-1) and blocks binding to intercellular adhesion molecule-1. J Immunol 167:3099–3106

    Article  Google Scholar 

  21. Bechard D, Meignin V, Scherpereel A et al (2000) Characterization of the secreted form of endothelial cell-specific molecule 1 by specific monoclonal antibodies. J Vasc Res 37:417–425

    Article  CAS  Google Scholar 

  22. Rocha SF, Schiller M, Jing D et al (2014) Esm1 modulates endothelial tip cell behavior and vascular permeability by enhancing VEGF bioavailability. Circ Res 115:581–590

    Article  CAS  Google Scholar 

  23. Qiu C-R, Fu Q, Sui J et al (2016) Serum endothelial cell specific molecule 1 (Endocan) levels in patients with acute myocardial ınfarction and ıts clinical significance: a pilot study. Angiology 1–6.

  24. Wang X, Yang W, Luo T, Wang J, Jing Y (2015) Serum endocan levels are correlated with the presence and severity of coronary artery disease in patients with hypertension. Genet Test Mol Biomarkers 19:124–127

    Article  CAS  Google Scholar 

  25. Kundi H, Balun A, Cicekcioglu H et al. (2016) Admission endocan level may be a useful predictor for ın-hospital mortality and coronary severity ındex in patients with ST-segment elevation myocardial ınfarction. Angiology 1–6.

  26. Balta S, Mikhailidis DP, Demirkol S, Ozturk C, Celik T, Iyisoy A (2015) Endocan: a novel inflammatory indicator in cardiovascular disease? Atherosclerosis 243:339–343. https://doi.org/10.1016/j.atherosclerosis.2015.09.030

    Article  CAS  PubMed  Google Scholar 

  27. Balta S, Mikhailidis DP, Demirkol S et al (2014) Endocan–a novel inflammatory indicator in newly diagnosed patients with hypertension: a pilot study. Angiology 65:773–777

    Article  Google Scholar 

  28. Yilmaz MI, Siriopol D, Saglam M et al (2014) Plasma endocan levels associate with inflammation, vascular abnormalities, cardiovascular events, and survival in chronic kidney disease. Kidney Int 86:1213–1220

    Article  CAS  Google Scholar 

  29. Icli A, Cure E, Cure MC et al (2016) Endocan levels and subclinical atherosclerosis in patients with systemic lupus erythematosus. Angiology 67:749–755

    Article  CAS  Google Scholar 

  30. Bicer M, Guler A, Unal Kocabas G, Imamoglu C et al (2017) Endocan is a predictor of increased cardiovascular risk in women with polycystic ovary syndrome. Endocr Res 42(2):145–153. https://doi.org/10.1080/07435800.2016.1255896

    Article  CAS  PubMed  Google Scholar 

  31. Tello-Montoliu A, Moltó JM, López-Hernandez N et al (2007) Common carotid artery intima-media thickness and intracranial pulsatility index in non-ST-elevation acute coronary syndromes. Cerebrovasc Dis 24:338–342

    Article  CAS  Google Scholar 

  32. Timóteo AT, Mota Carmo M, Ferreira RC (2012) Can metabolic syndrome presence predict carotid intima-media thickness? J Clin Hypertens (Greenwich) 14:507–513

    Article  Google Scholar 

  33. Van der Meer IM, Bots ML, Hofman A et al (2004) Predictive value of non-invasive measures of atherosclerosis for incident myocardial infarction. Circulation 109:1089–1094

    Article  Google Scholar 

  34. Tziomalos K, Athyros VG, Karagiannis A, Mikhailidis DP (2012) Lipid lowering agents and the endothelium: an update after 4 years. Curr Vasc Pharmacol 10:33–41

    Article  CAS  Google Scholar 

  35. Chang CL, Wu CH, Yao WJ et al (2011) Menopausal symptoms among healthy, middle-aged women as assessed with the Menopause Symptom Scale. Menopause 18:1113–1119

    Article  Google Scholar 

  36. Freeman EW, Sammel MD, Lin H et al (2010) Obesity and reproductive hormone levels in the transition to menopause. Menopause 17:718–726

    PubMed  PubMed Central  Google Scholar 

  37. Sutton-Tyrrell K, Wildman RP, Matthews KA et al (2005) Sex-hormone-binding globulin and the free androgen index are related to cardiovascular risk factors in multiethnic premenopausal and perimenopausal women enrolled in the Study of Women Across the Nation (SWAN). Circulation 111:1242–1249

    Article  CAS  Google Scholar 

  38. Wildman RP, Tepper PG, Crawford S et al (2012) Do changes in sex steroid hormones precede or follow increases in body weight during the menopause transition? Results from the Study of Women’s Health Across the Nation. J Clin Endocrinol Metab 97:E1695–E1704

    Article  CAS  Google Scholar 

  39. Pradhan AD, Manson JE, Rossouw JE et al (2002) Inflammatory biomarkers, hormone replacement therapy, and incident coronary heart disease: prospective analysis from the Women’s Health Initiative observational study. JAMA 288(8):980–987

    Article  CAS  Google Scholar 

  40. Hulley S, Grady D, Bush T et al (1998) Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement study (HERS) Research Group. JAMA 280:605–613

    Article  CAS  Google Scholar 

  41. Cagnacci A, Cannoletta M, Palma F, Zanin R et al (2012) Menopausal symptoms and risk factors for cardiovascular disease in postmenopause. Climacteric 15:157–162

    Article  CAS  Google Scholar 

Download references

Acknowledgements

We would like to thank American Journal Experts team for language editing assistance.

Funding

All the authors report neither funding nor financial support for this study.

Author information

Authors and Affiliations

  1. Department of Obstetrics and Gynecology, University of Health Sciences Istanbul, Bakirkoy Dr. Sadi Konuk Training and Research Hospital, 34180, Istanbul, Turkey

    Şükrü Yıldız, Cihan Kaya, İsmail Alay, Emine Öztürk, Aysun Fendal Tunca & Levent Yaşar

  2. Institute of Child Health, Istanbul University, Faculty of Medicine, 34200, Istanbul, Turkey

    Asuman Gedikbaşı

  3. Department of Obstetrics and Gynecology, Istanbul Aydin University, Faculty of Medicine, 34140, Istanbul, Turkey

    Hüseyin Cengiz

Authors
  1. Şükrü Yıldız
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Cihan Kaya
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Asuman Gedikbaşı
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Hüseyin Cengiz
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. İsmail Alay
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Emine Öztürk
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Aysun Fendal Tunca
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Levent Yaşar
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

SY contributed to concept, study design and manuscript writing. CK and HC contributed to concept and study design. IA, EO and AFT collected the data. AG and LY contributed to data analysis. All authors read and approved the submitted manuscript.

Corresponding author

Correspondence to Şükrü Yıldız.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Yıldız, Ş., Kaya, C., Gedikbaşı, A. et al. Endocan as a predictor of increased cardiovascular risk during the menopausal transition period. Arch Gynecol Obstet 301, 1553–1560 (2020). https://doi.org/10.1007/s00404-020-05520-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00404-020-05520-7

Keywords

Search

Navigation